EClinicalMedicine · 2024 · 25 citations · 28 references
MedicinePediatricsPharmacotherapyNeonatologyPediatric OphthalmologyPediatric PharmacotherapyInfant PharmacotherapyNeonatal PharmacologyNeonatal PharmacotherapyPediatric Retinal DisordersRetinal PharmacotherapyRetinopathy Of PrematurityAblative Laser TherapyAnti-vegf Ocular TherapyDrug Safety In InfantsIntravitreal Anti-vascular Endothelial Growth Factor TherapyOphthalmic Laser TherapyRetinal Angiogenesis InhibitionRetinopathy Of Prematurity PharmacotherapyVascular Endothelial Growth Factor
Background: Concerns remain over the long-term safety of vascular endothelial growth factor (VEGF) inhibitors to treat retinopathy of prematurity (ROP). RAINBOW is an open label randomised trial comparing intravitreal ranibizumab (in 0.2 mg and 0.1 mg doses) with laser therapy in very low birthweight infants (<1500 g) with ROP. Methods: Of 201 infants completing RAINBOW, 180 were enrolled in the RAINBOW Extension Study. At 5 years, children underwent ophthalmic, development and health assessments. The primary outcome was visual acuity in the better-seeing eye. The study is registered with ClinicalTrial.gov, NCT02640664. Findings: Between 16-6-2016 and 21-4-2022, 156 children (87%) were evaluated at 5 years. Of 32 children with no acuity test result, 25 had a preferential looking test, for 4 children investigators reported low vision for each eye, and in 3 further children no vision measurement was obtained. 124 children completed the acuity assessment, the least square mean (95% CI) letter score in the better seeing eye was similar in the three trial arms-66.8 (62.9-70.7) following ranibizumab 0.2 mg, 64.6 (60.6-68.5) following ranibizumab 0.1 mg and 62.1 (57.8-66.4) following laser therapy; differences in means: ranibizumab 0.2 mg v laser: 4.7 (95% CI: -1.1, 10.5); 0.1 mg v laser: 2.5 (-3.4, 8.3); 0.2 mg v 0.1 mg: 2.2 (-3.3, 7.8). High myopia (worse than -5 dioptres) in at least one eye occurred in 4/52 (8%) children following ranibizumab 0.2 mg, 8/55 (15%) following ranibizumab 0.1 mg and 11/45 (24%) following laser therapy (0.2 mg versus laser: odds ratio: 3.99 (1.16-13.72)). Ocular and systemic secondary outcomes and adverse events were distributed similarly in each trial arm. Interpretation: 5-year outcomes confirm the findings of the original RAINBOW trial and a planned interim analysis at 2 years, including a reduced frequency of high myopia following ranibizumab treatment. No effects of treatment on non-ocular outcomes were detected. Funding: Novartis Pharma AG.
28
Validation of a Model of Gross Motor Function for Children With Cerebral Palsy
Robert J. Palisano, Steven Hanna, Peter Rosenbaum et al. · Physical Therapy · 2000 · 947 citations · Full text
Medicine, Child Health, Pediatrics +17
A computerized method of visual acuity testing
Roy W. Beck, Pamela S. Moke, Andrew Turpin et al. · American Journal of Ophthalmology · 2003 · 600 citations
Medicine, Ophthalmology, Optometry +12
Andreas Stahl, Domenico Lepore, Alistair R. Fielder et al. · The Lancet · 2019 · 433 citations · Full text
Medicine, Ophthalmology, Pediatrics +14
Robert L. Avery, Alessandro Castellarin, Nathan Steinle et al. · British Journal of Ophthalmology · 2014 · 374 citations · Full text